[go: up one dir, main page]

WO2001075179A3 - Preprocalcitonin as tumor rejection antigen precursor and uses thereof - Google Patents

Preprocalcitonin as tumor rejection antigen precursor and uses thereof Download PDF

Info

Publication number
WO2001075179A3
WO2001075179A3 PCT/US2001/040288 US0140288W WO0175179A3 WO 2001075179 A3 WO2001075179 A3 WO 2001075179A3 US 0140288 W US0140288 W US 0140288W WO 0175179 A3 WO0175179 A3 WO 0175179A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor rejection
rejection antigen
preprocalcitonin
antigen precursor
precursor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/040288
Other languages
French (fr)
Other versions
WO2001075179A2 (en
Inventor
Hamid Echchakir
Fathia Mami-Chouaib
Isabelle Vergnon
Salem Chouaib
Jean Francois Baurain
Pierre G Coulie
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
Institut Gustave Roussy (IGR)
Institut National de la Sante et de la Recherche Medicale INSERM
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Institut Gustave Roussy (IGR), Institut National de la Sante et de la Recherche Medicale INSERM, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Priority to EP01927400A priority Critical patent/EP1301624A2/en
Priority to AU2001253852A priority patent/AU2001253852A1/en
Publication of WO2001075179A2 publication Critical patent/WO2001075179A2/en
Anticipated expiration legal-status Critical
Publication of WO2001075179A3 publication Critical patent/WO2001075179A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to the identification of a tumor rejection antigen precursor. It has been established that preprocalcitonin protein functions as a tumor rejection antigen precursor, and is processed to at least one tumor rejection antigen. Complexes of the tumor rejection antigen and an MHC molecule are recognized by cytolytic T lymphocytes, and lysed.
PCT/US2001/040288 2000-03-31 2001-03-14 Preprocalcitonin as tumor rejection antigen precursor and uses thereof Ceased WO2001075179A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01927400A EP1301624A2 (en) 2000-03-31 2001-03-14 Preprocalcitonin as tumor rejection antigen precursor and uses thereof
AU2001253852A AU2001253852A1 (en) 2000-03-31 2001-03-14 Preprocalcitonin as tumor rejection antigen precursor and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53956700A 2000-03-31 2000-03-31
US09/539,567 2000-03-31

Publications (2)

Publication Number Publication Date
WO2001075179A2 WO2001075179A2 (en) 2001-10-11
WO2001075179A3 true WO2001075179A3 (en) 2003-02-06

Family

ID=24151778

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/040288 Ceased WO2001075179A2 (en) 2000-03-31 2001-03-14 Preprocalcitonin as tumor rejection antigen precursor and uses thereof

Country Status (3)

Country Link
EP (1) EP1301624A2 (en)
AU (1) AU2001253852A1 (en)
WO (1) WO2001075179A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504850A (en) * 2004-06-16 2008-02-21 アフィナジー， インコーポレイテッド IFBM for promoting specific adhesion of a target analyte to the surface of an orthopedic implant
EP2006384A1 (en) * 2007-06-22 2008-12-24 Institut Gustave Roussy Preprocalcitonin-derived antigen epitopes
US20130046085A1 (en) * 2011-06-22 2013-02-21 Universidad De Sevilla Antibodies against n-procalcitonin
EP3115058A1 (en) * 2015-07-09 2017-01-11 Institut Gustave Roussy Immunogenic preprocalcitonin peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520794A1 (en) * 1991-06-26 1992-12-30 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
WO1997025622A1 (en) * 1996-01-12 1997-07-17 B.R.A.H.M.S. Diagnostica Gmbh Diagnostic method for determining the etiology of inflammatory processes
WO1998033524A1 (en) * 1997-02-03 1998-08-06 Endocrinology Associates-Australia Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520794A1 (en) * 1991-06-26 1992-12-30 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
WO1997025622A1 (en) * 1996-01-12 1997-07-17 B.R.A.H.M.S. Diagnostica Gmbh Diagnostic method for determining the etiology of inflammatory processes
WO1998033524A1 (en) * 1997-02-03 1998-08-06 Endocrinology Associates-Australia Llc Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
EDBROOKE M R ET AL: "EXPRESSION OF THE HUMAN CALCITONIN-CALCITONIN GENE RELATED PEPTIDE GENE IN LUNG AND THYROID CARCINOMA", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 4, no. 3, 1985, pages 715 - 724, XP008003708, ISSN: 0261-4189 *
ICHIKI S ET AL: "PRODUCTION OF IMMUNOREACTIVITY CALCITONIN AND SOME OTHER TUMOR MARKERS BY ESTABLISHED HUMAN CARCINOMA CELL LINES", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 77, no. 3, 1986, pages 270 - 275, XP008003477, ISSN: 0910-5050 *
KELLEY MICHAEL J ET AL: "Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides.", CANCER LETTERS, vol. 81, no. 1, 1994, pages 19 - 25, XP008003713, ISSN: 0304-3835 *
LUSTER W ET AL: "DEMONSTRATION OF IMMUNO REACTIVE CALCITONIN IN SERA AND TISSUES OF LUNG CANCER PATIENTS", EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, vol. 18, no. 12, 1982, pages 1275 - 1284, XP008003714, ISSN: 0277-5379 *
TAKANO TORU ET AL: "Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 84, no. 3, March 1999 (1999-03-01), pages 951 - 955, XP002200565, ISSN: 0021-972X *
WHANG KEVIN T ET AL: "Serum calcitonin precursors in sepsis and systemic inflammation.", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 83, no. 9, 1998, pages 3296 - 3301, XP002200569, ISSN: 0021-972X *

Also Published As

Publication number Publication date
WO2001075179A2 (en) 2001-10-11
EP1301624A2 (en) 2003-04-16
AU2001253852A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
WO2001047959A3 (en) Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
AU2001233027A1 (en) Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2001014424A3 (en) Human ctla-4 antibodies and their uses
ZA200407868B (en) 17alpha-Alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations.
WO2004048399A3 (en) Skin or hair binding peptides
CA2266319A1 (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
EP2172476A3 (en) Compositions and methods for WT1 specific immunotherapy
WO2002057293A3 (en) Modified zinc finger binding proteins
MXPA03002480A (en) Immunogen comprising ligand bound hiv envelpe protein.
WO2002102586A3 (en) Cellulose-polymer composites and methods for manufacturing same
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
AU2001244609A1 (en) Novel protein, dna thereof and process for producing the same
WO2003038397A3 (en) Assay
WO1999064464A3 (en) Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means
AU2001295483A1 (en) Solid peptide preparations for inhalation, and the production thereof
EP1128162A3 (en) Navigation device
DE69932182D1 (en) PREPARATIONS CONTAINING VIRUS-SIMILAR PARTICLES AS IMMUNOTPOTENTIATORS AND DELIVERED THROUGH THE SCHLEIMHAUT.
WO2001075179A3 (en) Preprocalcitonin as tumor rejection antigen precursor and uses thereof
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
WO2002031512A3 (en) Molecular interactions in hematopoietic cells
AU4990999A (en) Survivin, and peptides thereof, as an anti-cancer vaccine
WO2002026785A3 (en) Epitopes of virus hepatitis c specifically cd4+ t lymphocytes
IL147810A0 (en) Antitumor antibodies, proteins and uses thereof
AU2001273950A1 (en) Antibodies against native gp96, production and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CN JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001927400

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001927400

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001927400

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP